Orbus Therapeutics Reports the P-III (STELLAR) Trial Data of Eflornithine Plus Lomustine to Treat Recurrent Astrocytoma IDH Mutant Grade 3
Shots:
- The P-III (STELLAR) trial assessed eflornithine + lomustine vs lomustine alone in patients (n= 343) with recurrent anaplastic astrocytoma, incl. 194 with grade 3 IDH mutant astrocytoma across >105 trial centers in 8 countries
- In the study, OS in the ITT population was not statistically significant; however, meaningful improvements in both OS & PFS were seen among 194 patients with recurrent grade 3 IDH mutant astrocytoma, with mOS of 34.9 vs 23.5mos. & mPFS of 15.8 vs 7.2mos.
- Regimen was well-tolerated, with side effects consistent with earlier studies; common Grade 3+ TEAEs included myelosuppression & hearing impairment, without unexpected safety signals. Data will be highlighted at future conferences
Ref: Orbus | Image: Orbus
Related News; AstraZeneca Provides Update on P-III (CAPItello-281) Study of Truqap Regimen in PTEN-Deficient mHSPC-
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
